VIDEO: Study evaluates adjuvant bevacizumab duration in ovarian cancer
Click Here to Manage Email Alerts
In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, spoke with Healio about findings from a study examining survival with longer vs. shorter duration of bevacizumab therapy in patients with advanced ovarian cancer.
For the study, the researchers randomly assigned patients to receive adjuvant bevacizumab (Avastin, Genentech) for 15 or 30 months.
Both regimens were generally well tolerated, Annunziata noted, but OS was “essentially the same” between treatment arms.
“The conclusion from this study is that 15 months of bevacizumab is really enough,” Annunziata said.
Collapse
Pfisterer J, et al. Abstract 5501. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts